04.01.2024 14:30:03
|
EQS-PVR: PharmaSGP Holding SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: PharmaSGP Holding SE
Notification of Major Holdings
1. Details of issuer
2. Reason for notification
3. Details of person subject to the notification obligation
4. Names of shareholder(s) holding directly 3% or more voting rights, if different from 3. 5. Date on which threshold was crossed or reached:
6. Total positions
7. Details on total positions a. Voting rights attached to shares (Sec. 33, 34 WpHG)
b.1. Instruments according to Sec. 38 (1) no. 1 WpHG
b.2. Instruments according to Sec. 38 (1) no. 2 WpHG
8. Information in relation to the person subject to the notification obligation
9. In case of proxy voting according to Sec. 34 para. 3 WpHG (only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG) Date of general meeting: Holding total positions after general meeting (6.) after annual general meeting:
10. Other explanatory remarks: Date
04.01.2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | PharmaSGP Holding SE |
Lochhamer Schlag 1 | |
82166 Gräfelfing | |
Germany | |
Internet: | https://pharmasgp.com |
End of News | EQS News Service |
|
1808489 04.01.2024 CET/CEST
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu PharmaSGPmehr Nachrichten
27.11.24 |
Ausblick: PharmaSGP legt Quartalsergebnis vor (finanzen.net) | |
25.11.24 |
EQS-DD: PharmaSGP Holding SE: FUTRUE GmbH, Kauf (EQS Group) | |
25.11.24 |
EQS-DD: PharmaSGP Holding SE: FUTRUE GmbH, buy (EQS Group) | |
14.11.24 |
EQS-News: PharmaSGP with strong revenues growth in 9M 2024 – revenues forecast for FY 2024 raised (EQS Group) | |
14.11.24 |
EQS-News: PharmaSGP mit kräftigem Umsatzwachstum in 9M 2024 – Erhöhung der Umsatzprognose für FY 2024 (EQS Group) | |
05.11.24 |
EQS-News: CEO-Wechsel bei der PharmaSGP Holding SE: Peter Gerckens folgt zum 01. Januar 2025 auf Natalie Weigand (EQS Group) | |
05.11.24 |
EQS-News: CEO change at PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as of January 1, 2025 (EQS Group) | |
05.11.24 |
EQS-Adhoc: PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as Chief Executive Officer (EQS Group) |
Analysen zu PharmaSGPmehr Analysen
Aktien in diesem Artikel
PharmaSGP | 27,80 | 0,72% |
|